In a 12-month period before and after erenumab use, patients with chronic migraine decreased HRU and use of acute and traditional migraine preventive medications.
Amitava Banerjee and colleagues argue that the long term impact of non-communicable diseases should be prioritised in planning the response to and management of future health shocks ### Key messages ...
Findings from UK burosumab early access program spotlighted in oral presentation at ASBMR annual meetingStatistically significant improvements seen in patient-reported measures of pain, stiffness, ...